PARIS and TARRYTOWN, N.Y., April 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.

Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival.

VANCOUVER, March 28, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted a U.S.

The drug oxaliplatin is a major reason the prognosis for metastatic colon cancer has gone from an expected survival of several months to a couple years.

CAMBRIDGE, Mass., Jan. 12, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.